Comparing the current results to its competitors, Tarsus Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 69.41 % year on year. The revenue growth was below Tarsus Pharmaceuticals Inc 's competitors' average revenue growth of 69.75 %, achieved in the same quarter.
Tarsus Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates within the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancement, significant competition, and a focus on intellectual property. Its competitors include major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions. Key competitive factors include efficacy, combinability, safety profile, convenience, cost, promotional activity, and intellectual property protection. Currently, aside from XDEMVY, there are no other on-label prescription pharmaceutical treatments available for blepharitis or Demodex blepharitis in the U.S., with existing treatments consisting of over-the-counter and off-label options.
January 13, 2025
In an ambitious update, Tarsus Pharmaceuticals delineated its strategic progress toward establishing ocular rosacea as a pivotal therapeutic opportunity within the eye care sector, targeting launch dates as early as 2025. The definitive plan includes advancing their novel treatment candidate, TP-04 (lotilaner ophthalmic gel), through the initiation of a Phase 2 clinical study projected for the second half of 2025. This approach positions Tarsus to potentially address a significant gap in treatment options for a condition that currently lacks any FDA-approved therapies.Ocular rosacea, a chronic inflammatory condition often linked to dermatological rosacea, is characterized by symptoms such as ocular irritatio...
April 23, 2024
Tarsus Pharmaceuticals Secures $200 Million Financing Commitment from Pharmakon, Bolstering Financial PositionIRVINE, Calif., April 23, 2024 - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company dedicated to addressing unmet medical needs and leveraging innovative science and technology to revolutionize patient care, has announced today its successful acquisition of $200 million in committed capital from funds associated with Pharmakon Advisors, LP. This strategic financial move allows Tarsus to strengthen its financial position and refinances its existing debt, marking a significant milestone in the company s growth.Tarsus Pharmaceuticals is at the forefront of the industry, with a mission to transform e...
February 22, 2024
Tarsus TP-05 Shows Promising Results in Phase 2a Trial: A Potential Breakthrough in Lyme Disease ProphylaxisLyme disease, caused by the spirochete bacterium Borrelia burgdorferi, is a significant public health concern in many parts of the world, particularly in regions where ticks thrive. It is transmitted to humans primarily through the bite of infected blacklegged ticks (Ixodes scapularis and Ixodes pacificus) commonly found in North America and Europe. As the number of Lyme disease cases continues to rise, there is a pressing need for effective preventive measures to combat this debilitating illness. In this context, Tarsus Pharmaceuticals has made exciting progress with their investigational drug TP-05 ...
December 11, 2023
Tarsus Pharmaceuticals Reports Promising Results from Ersa Phase 2a Clinical Trial in Treating Meibomian Gland Disease Tarsus Pharmaceuticals Inc. recently announced positive topline results from its Ersa Phase 2a clinical trial evaluating TP-03 as a treatment for Meibomian Gland Disease (MGD) in patients with Demodex mites. The study demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, irrespective of BID (twice a day) or TID (three times a day) dosing. Additionally, TP-03 was well tolerated among the participants. Meibomian Gland Disease is a common chronic condition that affects the quality and quantity of the tears produced by the Mei...
Publicly Traded Peers of Tarsus Pharmaceuticals Inc
Aldeyra Therapeutics Inc Share Performance
-73.38%
One Year
Aldeyra Therapeutics Inc
Profile
Aldeyra Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative therapies for rare diseases associated with immune-mediated conditions using their proprietary compounds and technology.
Biostage Inc is a company that aims to develop and commercialize bioengineered organ implants for the treatment of life-threatening conditions. They utilize their proprietary CellFrame technology to create personalized, implantable organs that can potentially restore and regenerate damaged tissue.
Eyepoint Pharmaceuticals Inc is a pharmaceutical company that operates on a specialty business model focused on advancing ophthalmic therapies. They develop and commercialize innovative treatments using their proprietary drug delivery technology, allowing for sustained release of drugs to the eye. By leveraging their expertise in ophthalmology and controlled release technology, Eyepoint aims to improve patient outcomes and address unmet medical needs in eye care.
Ocular Therapeutix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. They utilize their proprietary hydrogel technology to design and manufacture sustained-release treatments that can be administered during routine eye exams and eliminate the need for patient compliance with eye drops.
Sources:
Tarsus Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tarsus Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
